Supplementary Data from Association of AXL and PD-L1 Expression with Clinical Outcomes in Patients with Advanced Renal Cell Carcinoma Treated with PD-1 Blockade

Abstract

<p>This file contains 6 supplementary figures and 5 supplementary Tables. <b>Supplementary Figure S1</b> - Protein expression pattern of AXL in ccRCC specimens. <b>Supplementary Figure S2</b> - Response rates, Survival and Biomarker analyses according to AXLneg, AXLlow and AXLhigh expression <b>Supplementary Figure S3</b> - ORR and Progression-Free Survival according to PD-L1 Status alone or by grouping AXL expression plus PD-L1 status <b>Supplementary Figure S4</b> - High AXL expression plus PD-L1 TC positivity is associated with worse OS in Nivolumab-treated patients in IMDC intermediate-risk/poor-risk group <b>Supplementary Figure S5</b> - VHL status does not interfere with outcomes or AXL expression upon treatment with Nivolumab <b>Supplementary Figure S6</b> - Biomarker distribution across AXL groups stratified based on VHL status</p>